Injectable pharmaceutical composition and use thereof
By suspending injectable compositions of moxifenin microspheres and isoxazoline compound particles in aqueous carriers, the problems of maintaining isoxazoline and moxifenin concentrations and stimulating the injection site in a single injection are solved, and the problem of stimulation of the injection site is achieved. Long-term stable release and safety ensure effective treatment of parasites.
Patent Information
- Application Number
- CN202080033087.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-05-03
- Filing Date
- 2020-05-01
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2040-05-01
AI Technical Summary
The prior art is difficult to maintain effective concentrations of isoxazoline compounds and moxifenin in animal plasma effectively and safely in single injections, and the risk of irritation at the injection site is high, and it is difficult to ensure the physical and chemical stability of the formulation. sex.
Injectable compositions containing moxifenin microspheres and isoxazoline compound particles, composed of 50% to 99% fat or wax, the particles are suspended in an aqueous carrier, including suspension agents, wetting agents and Preservatives, atomizing and gamma radiation sterilizing, form a stable suspension to ensure long-term release and safety.
Achieve long-term stable release of isoxazoline compounds and moxifenin, reduces the risk of stimulation at the injection site, ensures the physical and chemical stability of the preparation, and maintains biological activity through gamma radiation sterilization, providing parasites effective treatment and prevention.
Smart Images

Figure CN113784702B_ABST
Abstract
Description
Background Art
[0001] Isoxazoline compounds are known in the art, and these compounds and their use as antiparasitic agents are described, for example, in U.S. Patent Application US 2007 / 0066617 and International Patent Applications WO 2005 / 085216, WO 2007 / 079162, WO 2009 / 002809, WO 2009 / 024541, WO 2009 / 003075, WO 2010 / 070068 and WO 2010 / 079077, the disclosures of which and the references cited herein are incorporated by reference. Such compounds are known to have excellent activity against ectoparasitic arthropods.
[0002] WO2015 / 048371 discloses a long-acting injectable composition comprising a spirocyclicisoxazoline compound, a biopolymer and at least one carrier, solvent or excipient.
[0003] WO2016 / 138339 discloses a long-acting injectable formulation comprising at least one isoxazoline active agent, a poloxamer and a co-solvent.
[0004] WO2016 / 164487 discloses an extended release injectable veterinary formulation for combating parasites, comprising at least one isoxazoline active agent, a pharmaceutically acceptable polymer and a solvent.
[0005] US Patent No. 9,609,869 discloses insecticidal compounds based on isoxazoline derivatives for use in controlling pests associated with agriculture, horticulture, animal husbandry, and companion animals.
[0006] U.S. Patent Application Publication No. 2017 / 0239218 discloses a long-acting injectable composition for combating parasites comprising at least one isoxazoline active agent, liquid PEG and / or a neutral oil.
[0007] Another ectoparasitic compound has recently been described: 2-chloro-N-(1-cyanocyclopropyl)-5-[1'-methyl-3'-(1,1,2,2,2-pentafluoroethyl)-4'-(trifluoromethyl)[1,5'-bis-1H-pyrazol]-4-yl]benzamide; Tigolaner (CAS RN 1621436-41-6) which is disclosed in WO2019 / 012377.
[0008] Moxidectin is an active ingredient that is useful for preventing and treating infections and infestations caused by helminths, nematodes, mites and endo- and ecto-parasitic arthropods, particularly when administered parenterally to animals.
[0009] Moxidectin has been disclosed in US Pat. No. 4,916, 154. EP0525307 and EP1197207 disclose moxidectin microspheres and injectable compositions and their preparation and use.
[0010] An advantageous injectable pharmaceutical composition for veterinary use would be one that would enable a single injection to provide effective concentration levels of both active compounds (moxidectin and isoxazoline compound) in the plasma of the treated animal over an extended period of time.
[0011] Besides the release duration of such compositions, technical characteristics of injectable veterinary formulations, such as ease of administration (syringability and resuspendability) and absence of side effects (local injection site reactions and systemic side effects after administration) and the possibility to sterilize the formulation are important features.
[0012] Therefore, it is desirable to have a technically feasible injectable formulation that allows for the effective and safe release of effective amounts of isoxazoline compounds and moxidectin as described above in a combined formulation over an extended period of time. This would allow the use of these modern compounds under conditions of single injection without the need for repeated dosing. The composition should also ensure that the excipients do not interfere with the moxidectin microspheres and provide a stable moxidectin content.
[0013]
[0006] Therefore, there is a need for injectable pharmaceutical compositions for the extended release of isoxazoline compounds and moxidectin that overcome one or more limitations of the prior art. Summary of the invention
[0014] Thus, the present invention provides an injectable composition comprising an isoxazoline compound and moxidectin microspheres having long-term efficacy against parasites, safety, physical and chemical stability, and reduced risk of injection site irritation.
[0015] One embodiment of the present invention is an injectable veterinary composition comprising
[0016] a) moxidectin microspheres comprising about 50 wt % to about 99 wt % of a fat, a wax or a mixture thereof, and 0.01-10 wt % of an antioxidant; and
[0017] b) Granules of the isoxazoline compound of formula (I)
[0018]
[0019] in
[0020] R 1 = halogen, CF3, OCF3, CN,
[0021] n=an integer from 0 to 3, preferably 1, 2 or 3,
[0022] R 2 =C1-C3-haloalkyl, preferably CF3 or CF2Cl,
[0023] T = 5 to 12 membered monocyclic or bicyclic ring system, which is optionally substituted by one or more groups Y,
[0024] Y = methyl, halomethyl, halogen, CN, NO2, NH2-C=S, or two adjacent groups Y together form a chain, especially a three-membered or four-membered chain;
[0025] Q=X-NR 3 R 4 or a 5-membered N-heteroaryl ring, which is optionally substituted with one or more groups;
[0026] X=CH2, CH(CH3), CH(CN), CO, CS,
[0027] R 3 =hydrogen, methyl, haloethyl, halopropyl, halobutyl, methoxymethyl, methoxyethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, N-phenyl-N-methyl-amino, haloethylaminocarbonylmethyl, haloethylaminocarbonylethyl, tetrahydrofuranyl, methylaminocarbonylmethyl, (N,N-dimethylamino)-carbonylmethyl, propylaminocarbonylmethyl, cyclopropylaminocarbonylmethyl, propenylaminocarbonylmethyl, haloethylaminocarbonylcyclopropyl,
[0028]
[0029]
[0030] Where Z A = hydrogen, halogen, cyano, halomethyl (CF3);
[0031] R 4 = hydrogen, ethyl, methoxymethyl, halomethoxymethyl, ethoxymethyl, haloethoxymethyl, propoxymethyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl, cyclopropylcarbonyl, ethoxycarbonyl, methoxyethylcarbonyl, aminocarbonyl, ethylaminocarbonylmethyl, ethylaminocarbonylethyl, dimethoxyethyl, propynylaminocarbonylmethyl, haloethylaminocarbonylmethyl, cyanomethylaminocarbonylmethyl, or haloethylaminocarbonylethyl;
[0032] or R 3 and R 4 Together they form a substituent selected from:
[0033]
[0034] or a salt or solvate thereof;
[0035] The moxidectin microspheres and isoxazoline compound particles are suspended in an aqueous carrier comprising one or more suspending agents, one or more wetting agents and / or one or more preservatives and water.
[0036] Another embodiment is a method of treating or preventing a parasitic infection in an animal comprising administering such an injectable veterinary composition to an animal in need thereof.
[0037] Another embodiment is a method of producing such an injectable veterinary composition, comprising the steps of:
[0038] a) preparing isoxazoline particles, preferably by crystallization;
[0039] b) preparing moxidectin microspheres by melting fat, wax or mixtures thereof and adding moxidectin and optionally an antioxidant and preparing the microspheres, preferably by spinning disk atomization and optionally sieving;
[0040] c) filling the moxidectin microspheres obtained in step b) and the isoxazoline particles obtained in step a) into a first container;
[0041] d) preparing an aqueous carrier by dissolving excipients including a suspending agent, a wetting agent and / or a preservative in water and filling into a second container;
[0042] e) Reconstitute the solid by transferring the aqueous carrier from the second container d) to the first container c) and shake to form a ready-to-use suspension.
[0043] Another embodiment is a kit, wherein the kit comprises:
[0044] a) a first container comprising a solid mixture of particles of the isoxazoline compound of formula (I) and moxidectin microspheres as described above;
[0045] b) a second container having an aqueous carrier comprising one or more suspending agents, wetting agents and / or preservatives and water; and
[0046] c) instructions for reconstituting the moxidectin microspheres and isoxazoline compound particles with an aqueous carrier prior to subcutaneous or intramuscular administration to an animal.
[0047] Another embodiment is a method of using such a kit to treat or prevent a parasitic infection in an animal by administering the reconstituted suspension to the animal by subcutaneous or intramuscular injection. BRIEF DESCRIPTION OF THE DRAWINGS
[0048] Figure 1: Scanning electron micrograph of 10% moxidectin in glyceryl tristearate microspheres (GTS)
[0049] Figure 2 and 3 : Plasma levels of moxidectin (2) and flurellanil (3) after subcutaneous administration to dogs
[0050] Detailed description
[0051] The present invention provides an injectable composition comprising an isoxazoline compound and moxidectin microspheres, which has long-term efficacy against parasites, safety, physical and chemical stability, and reduced risk of injection site irritation.
[0052] Physical stability of injectable suspensions is particularly important to allow correct dosing by injection of a uniform suspension containing the correct amounts of both isoxazoline compound and moxidectin in one common formulation. The inventors had to overcome the problem of different densities of two different solid components, isoxazoline (crystalline) particles and moxidectin microspheres - making it difficult to provide a uniform suspension. Chemical stability in formulation is particularly challenging for moxidectin.
[0053] A stable suspension should be formed which can be easily resuspended with the aqueous vehicle by gentle shaking without causing foaming or floating or settling of the suspended particles which would affect the accuracy of dosing.
[0054] Furthermore, it is important that the final composition to be injected remains physically (and chemically) stable throughout the period of use following resuspension / reconstitution.
[0055] Additionally, it would be advantageous if the injection was safe for the animal and did not cause adverse effects, particularly unacceptable injection site irritation, following injection.
[0056] More importantly, the composition can be sterilized by known and accepted procedures since it is to be administered by injection.
[0057] The present invention provides such an advantageous composition.
[0058] Isoxazoline compounds are known in the art, and such compounds are known to have excellent activity against parasitic infections such as ticks and fleas. Provided below are various embodiments of isoxazoline compounds useful in the present invention.
[0059] Injection site irritation is the damage that occurs at the injection site and surrounding tissue when an animal receives an injection of a pharmaceutical composition. This damage can be swelling, skin discoloration, and tissue necrosis. Although some injection site irritation is unavoidable in some animals, veterinarians and animal owners generally consider injection site swelling of more than 2×2 cm that persists for more than 2 to 3 days to be unacceptable. Minimal injection site irritation means injection site irritation of less than 2×2 cm that persists for less than 2 to 3 days. Veterinarians and their clients generally accept this standard in the case of animals receiving injections such as rabies vaccines.
[0060] As used herein, reported particle size data are volume weighted as measured by conventional particle techniques well known to those skilled in the art, such as static light scattering (also known as laser diffraction), image analysis, or sieving. Further discussion of particle size measurement is provided below.
[0061] Injectable means that the suspension can be easily withdrawn from the ampoule / vial / container into a syringe with a needle and subsequently injected from such syringe through a needle (eg, an 18-gauge needle) intramuscularly (im) or subcutaneously (sc).
[0062] The particle size of the active ingredient in the suspension can affect resuspension and injectability, that is, it should be small enough to prevent compaction or agglomeration and facilitate resuspension.
[0063] Pharmaceutically acceptable excipients are inert substances that form the vehicle or medium for the drug product.
[0064] A parasite "infestation" refers to the presence of parasites in numbers that pose a risk to humans or animals. The presence may be in the environment, such as in the animal's bedding, on the animal's skin or fur, etc. When the infestation referred to is within the animal, such as in the blood or other internal tissues, the term infestation is also intended to be synonymous with the term "infection," as that term is commonly understood in the art, unless otherwise indicated.
[0065] An aqueous suspension means a composition comprising particles which are mixed with, but not dissolved in, an aqueous liquid comprising water or a water-miscible liquid.
[0066] A liquid aqueous vehicle is an aqueous carrier or inert medium used as a solvent (or diluent) in which an active agent is formulated and / or administered.
[0067] A reconstitutable (or resuspendable) formulation is one in which a liquid vehicle is in one container, one or more active ingredients are solid in another container, and the contents of the two containers are combined at some point prior to administration to an animal to form a liquid solution or suspension final formulation.
[0068] Reconstitution is the process of adding liquid / diluent to dry ingredients to prepare a solution or suspension.
[0069] Aqueous liquid vehicles contain certain excipients used in formulation, such as one or more aqueous diluents, a suspending agent, one or more wetting agents, one or more preservatives, and the like.
[0070] The pharmaceutical compositions of the present invention are of particular value in controlling ectoparasites, ie, arthropods that are harmful to humans, livestock and companion animals or that transmit disease or act as vectors of disease in humans, livestock and companion animals.
[0071] Important arthropod parasites - ectoparasites (insect and acarid pests) are described in more detail below.
[0072] Biting insects include, for example, migrating diperous larvae, such as Hypoderma sp., Gastrophilus sp. in horses and Cuterebra sp. in rodents, as well as various types of biting flies and mosquitoes spp., for example, blood-sucking adults including, for example, horn flies or western horn flies (Haematobia irritans), horse flies or tabanus spp., stable flies or stable flies Stomoxyscalcitrans, black flies or gnats (Simulium spp.), spotted flies or spotted flies (Chrysops spp.), tick flies or sheep tick flies (Melophagus ovinus), tsetse flies or tsetse flies (Glossina spp.). Parasitic fly maggots include, for example, skin flies (Oestris ovis and Cuterebra spp.), blow flies or Phaenicia spp., spin flies or Cochliomyia hominivorax, cattle grubs or Hypoderma spp., and fleeceworms. Mosquitoes include, for example, Culex spp., Anopheles spp., and Aedes spp.
[0073] Mites include chicken mites, Dermanyssus gallinae; itch mites or scab mites or scabies mites (Astigmata), such as Sarcoptidae spp., for example, Sarcoptes scabiei; scabies mites, such as Psoroptidae spp., including Chorioptes bovis, Psoroptes ovis and Demodex canis; ear mites Otodectes cynotis; chiggers, such as Trombiculidae spp., for example, Trombicula aifreddugesi.
[0074] Ticks include, for example, soft-bodied ticks, including Argasidae spp., such as Argas spp. and Ornithodoros spp.; hard-bodied ticks, including Ixodidae spp., such as Ixodes ricinus, Ixodes scapularis, Rhipicephalus sanguineus, Haemaphysalis spp., Dermacentor reticulatus; Dermacentor variabilis, Amblyomma americanum, and Boophilus spp.
[0075] Lice include, for example, sucking lice, such as Menopon spp. and Bovicola spp.; biting lice, such as Haematopinus spp., Linognathus spp. and Solenopotes spp.
[0076] Fleas include, for example, Ctenocephalides spp., such as dog fleas (Ctenocephalides canis) and cat fleas (Ctenocephalides fells); Xenopsylla spp., such as oriental rat fleas (Xenopsylla cheopis); and Pulex spp., such as human fleas (Pulex irritans).
[0077] True bed bugs include, for example, Cimicidae or, for example, the common bed bug (Cimexlectularius); Triatominae spp. include cone bugs, also known as kissing bugs; for example, Rhodnius prolixus and Triatoma spp.
[0078] The compositions of the invention are valuable for treating and controlling various life cycle stages of parasites, including eggs, nymphs and larvae, juveniles and adult stages.
[0079] For the avoidance of doubt, "treatment" as used herein includes both curative and palliative treatment and "controlling ectoparasites" includes killing, repelling, expelling, incapacitating, preventing, eliminating, reducing, minimizing, eradicating pests on animals and in the animal's environment.
[0080] Prevention is the prevention of the establishment of new or incoming infestations or infections.
[0081] "Controlling an ectoparasite infestation" means wholly or partially preventing an infestation or alleviating or reducing the number of parasites in and / or on an animal and / or inhibiting the development of a parasite infestation in or on an animal.
[0082] "Controlling endoparasite infestation" means completely or partially alleviating or reducing the number of endoparasites, such as nematode and cestode parasites, in and / or on an animal and / or inhibiting the development of a parasite infestation in or on an animal.
[0083] Efficacy against endoparasites can be assessed by enumerating endoparasites, particularly helminths, directly following necropsy of the host animal.
[0084] The reduction of parasite numbers, particularly gastrointestinal helminth parasites, may alternatively be measured indirectly by fecal egg or differential larval counts. In this case, the effective amount of the composition is determined by the reduction in the number of helminth eggs or larvae excreted in the feces of the treated animal before and after treatment.
[0085] The composition of the present invention is administered by parenteral injection. The concentration of the active ingredient in the composition needs to be sufficient to provide the desired therapeutic or preventive effective amount, and its volume depends on the amount of injectable administration acceptable to the animal to be treated.
[0086] The composition according to the invention is useful for treating helminth infections, for example infections caused by one or more helminths selected from:
[0087] Ancylostoma spp.; Anecator spp.; Ascaridia spp.; Ascaris spp.; Brugia spp.; Bunostomum spp.; Capillaria spp.; Chabertia spp.; Cooperia spp.; Cyathostomum spp.; Cylicocyclus spp.; Cylicodontophorus spp.; Cylicostephanus spp.; Craterostomum spp.; Dictyocaulus spp.; Dipetalonema spp.; Dirofilaria spp.; Dracunculus spp.; Enterobius spp.; Filaria spp.; Habronema spp.; Haemonchus spp.; Heterakis spp.; Hyostrongylus spp.; Metastrongylus spp.; Meullerius spp.; Necator spp.; Nematodirus spp.; Nippostrongylus spp.; Oesophagostomum spp.; Onchocerca spp.; Ostertagia spp. spp.; Oxyuris spp.; Parascaris spp.; Stephanurus spp.; Strongylus spp.; Syngamus spp.; Toxocara spp.; Strongyloides spp.; Teledorsagia spp.; Toxascaris spp.; Trichinella spp.; Trichuris spp.; Trichostrongylus spp.); Triodontophorous spp.; Uncinaria spp. and Wuchereria spp.
[0088] Another serious internal parasite that harms animals is Dirofilaria immitis, also known as heartworm. The most common hosts are dogs and cats, but other animals such as ferrets and raccoons can also be infected. The parasite is spread through the bite of mosquitoes, which carry the heartworm larvae. The adult worms live in the major blood vessels of the lungs, causing inflammation of the blood vessels and potentially leading to heart damage and early death. In advanced infections, the worms also move into the heart.
[0089] In a particularly preferred embodiment of the present invention, the compositions of the present invention are used to treat or prevent infection by Dirofilaria immitis. In another embodiment, the compounds and compositions of the present invention are used to treat or prevent infection by Dirofilaria repens.
[0090] The control or "efficacy" of a compound refers to an amount that reduces parasite counts by 5% to about 100% after the first application. The control of arthropods (e.g., insects, mites) can be insecticidal and / or acaricidal. The effect of the compounds of the invention can be, for example, ovicidal, larvicidal, nymphicidal and / or adulticidal, or a combination thereof.
[0091] The effect may be direct, i.e. by killing the parasites immediately or after a period of time, for example when molting occurs, or by destroying their eggs, or indirect, for example by reducing the number of eggs laid and / or the hatching rate.
[0092] For in vivo administration of the compounds according to the present invention, an effective amount is synonymous with a "pharmaceutically effective amount", which is a dose or amount that completely or partially treats or improves the symptoms and / or signs of parasitic infection or infestation of the treated animal or reduces the number of parasites in and / or on the body of the animal and / or inhibits the development of parasitic infestation in or on the body of the animal. The latter amount can also be easily determined by a person of ordinary skill in the art, for example, by observing or detecting changes in the clinical condition or behavior of the treated animal, and by observing or detecting relative changes in the number of parasites after such treatment.
[0093] Systemic administration of a drug means reaching the target (organ or parasite) via the bloodstream.
[0094] Animal refers to mammals, including companion animals. Companion animals (or pets) refer to dogs, cats or horses, especially dogs or cats.
[0095] In one embodiment, the isoxazoline compounds used in the present invention also include pharmaceutically acceptable salts, esters and / or N-oxides thereof. In addition, reference to an isoxazoline compound also refers to any of its polymorphic forms or stereoisomers.
[0096] In one embodiment, the pharmaceutical composition according to the present invention may employ a racemic mixture of the isoxazoline used in the present invention, which contains equal amounts of the enantiomers of such isoxazoline compound as described above.
[0097] Alternatively, the pharmaceutical composition may employ an isoxazoline compound containing a stereoisomer enriched compared to the racemic mixture, which is one of the enantiomers of the isoxazoline as defined herein.
[0098] In addition, pharmaceutical compositions may employ substantially pure stereoisomers of such isoxazoline compounds.Such enriched or purified stereoisomer preparations of isoxazolines for use in the present invention may be prepared by methods known in the art.
[0099] Examples are chemical methods using catalytic asymmetric synthesis, or the separation of diastereoisomeric salts (see, for example: WO 2009 / 063910 and JP 2011 / 051977, respectively).
[0100] The S-enantiomer is particularly preferred.
[0101] In one embodiment of the isoxazolines used in the present invention, T is selected from
[0102]
[0103] Wherein in T-1, T-3 and T-4, the group Y = hydrogen, halogen, methyl, halomethyl, ethyl or haloethyl.
[0104] In one embodiment of the isoxazolines used in the present invention, Q is selected from
[0105]
[0106] Where R 3 , R 4 , X and Z A As defined above, and
[0107]
[0108] In one embodiment, the isoxazolines used in the present invention are as shown in Table 1.
[0109] Table 1:
[0110]
[0111]
[0112] Table 1 (continued):
[0113]
[0114] In one embodiment, the isoxazolines used in the present invention are as shown in Table 2.
[0115] Table 2:
[0116]
[0117]
[0118] In one embodiment, the isoxazoline used in the present invention is the following compound:
[0119]
[0120] Where R 1a , R 1b , R 1c Independently of each other: hydrogen, Cl or CF3
[0121] Preferably, R 1a and R 1c is Cl or CF3, and R 1b It is hydrogen,
[0122] T is
[0123]
[0124] wherein Y is methyl, bromine, Cl, F, CN or C(S)NH2; n=1 or 2; and Q is as described above.
[0125] In one embodiment of the isoxazoline as defined herein, R 3 is H, and R 4 It is: -CH2-C(O)-NH-CH2-CF3, -CH2-C(O)-NH-CH2-CH3, -CH2-CH2-CF3 or -CH2-CF3.
[0126] In one embodiment of the pharmaceutical composition according to the present invention, the isoxazoline is one or more selected from fluralaner, afoxolaner, lotilaner or sarolaner. In another embodiment of the pharmaceutical composition according to the present invention, the isoxazoline compound is one or more selected from fluralaner, afoxolaner, tigolaner, lotilaner or sarolaner.
[0127] In one embodiment, the compound of formula (I) is 4-[5-(3,5-dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-2-methyl-N-[(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-benzamide (CAS RN864731-61-3-USAN fluralaner).
[0128] In another embodiment, the compound of formula (I) is 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthamide (CAS RN 1093861-60-9, USAN-afoxolaner) disclosed in WO2007 / 079162.
[0129] In one embodiment of the pharmaceutical composition according to the invention, the isoxazoline is lotilaner (CAS RN: 1369852-71-0; 3-methyl-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-5-[(5S)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]thiophene-2-carboxamide).
[0130] In one embodiment of the pharmaceutical composition according to the invention, the isoxazoline is sarolaner (CAS RN: 1398609-39-6; 1-(5'-((5S)-5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3'-H-spiro(azetidine-3,1'-(2)benzofuran)-1-yl)-2-(methylsulfonyl)ethanone).
[0131] In another embodiment, the compound of formula (I) is (Z)-4-[5-(3,5-dichlorophenyl)-5-trifluoromethyl-4,5-dihydroisoxazol-3-yl]-N-[(methoxyimino)methyl]-2-methylbenzamide (CAS RN 928789-76-8).
[0132] In another embodiment, the compound of formula (I) is 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-N-(thietan-3-yl)benzamide (CASRN 1164267-94-0) disclosed in WO2009 / 0080250.
[0133] In another embodiment, the compound of formula (I) is 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1-naphthamide (CAS RN 1093861-60-9, USAN-afoxolaner) disclosed in WO2007 / 079162.
[0134] In another embodiment, the compound of formula (I) is 5-[5-(3,5-dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-3-methyl-N-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-2-thiophenecarboxamide (CAS RN 1231754-09-8) disclosed in WO2010 / 070068.
[0135] In an alternative embodiment, the isoxazoline compound is 2-chloro-N-(1-cyanocyclopropyl)-5-[1'-methyl-3'-(1,1,2,2,2-pentafluoroethyl)-4'-(trifluoromethyl)[1,5'-di-1H-pyrazole]-4-yl]benzamide; Tigolaner (CAS RN 1621436-41-6), which is disclosed in WO 2019 / 012377.
[0136]
[0137] The isoxazoline compounds may exist in various isomeric forms. References to compounds for use in the present invention always include all possible isomeric forms of such compounds.
[0138] In one embodiment, the racemic form of the isoxazoline compound is present in the composition according to the invention. In another embodiment, the S-enantiomer is present.
[0139] In a particularly preferred embodiment, the S-enantiomer of flurellan is present.
[0140] In another preferred embodiment, the isoxazoline compound according to formula (I) is the (S)-enantiomer of afoxolaner (also known as esafoxolaner).
[0141] An important aspect of the present invention is the combination of isoxazoline compound particles with stable microspheres comprising moxidectin dissolved in a fat, wax or mixture thereof having a melting point in an aqueous suspension above about 40°C, preferably above about 50°C.
[0142] These moxidectin microspheres can be sterilized by gamma irradiation or electron beam without significant degradation.
[0143] Microspheres are small spherical particles with a diameter of 1-1000mm, composed of polymerized wax or other protective materials.
[0144] Preferred stable moxidectin microspheres for use in the injectable formulation according to the present invention contain about 75 wt% to 95 wt% fat, wax or mixtures thereof on a weight basis. Preferably, the microspheres contain about 1-25% moxidectin and about 0.01-1% antioxidant.
[0145] In an alternative embodiment, the composition comprises microspheres of different macrolide compounds as described herein, including but not limited to avermectins or milbemycins. In some embodiments, such avermectins or milbemycins are eprinomectin, avermectin, ivermectin, selamectin, milbemycin, milbemycin D or milbemycin oxime.
[0146] In one embodiment, the composition comprises flurellana in combination with eprinomectin, or flurellana in combination with milbemycin oxime, selamectin, or moxidectin.
[0147] In one embodiment, the composition comprises afoxolaner in combination with eprinomectin, or afoxolaner in combination with milbemycin oxime, selamectin, or moxidectin.
[0148] In one embodiment, the composition comprises sarolaner in combination with eprinomectin, or sarolaner in combination with milbemycin oxime, selamectin, or moxidectin.
[0149] In one embodiment, the composition comprises lotilaner in combination with eprinomectin, or lotilaner in combination with milbemycin oxime, selamectin, or milbemycin oxime, selamectin, or moxidectin.
[0150] Injectable compositions generally require sterilization prior to administration to animals. Gamma irradiation or electron beam irradiation are effective sterilization methods for eliminating microbial contaminants.
[0151] However, moxidectin readily degrades upon irradiation and loses much of its biological activity. This destructive and degradative response to radiation precludes the use of gamma radiation or electron beams as a means of sterilizing certain moxidectin-containing compositions.
[0152] Moxidectin microspheres can be irradiated sterilized for injection as shown in Example 2 without negatively affecting the stability of the active ingredient. The moxidectin microspheres comprise or consist essentially of about 50% to 99% by weight of a fat, wax, or mixture thereof having a melting point above about 40°C, about 1% to 50% moxidectin, and about 0.01-10% of an antioxidant.
[0153] The injectable pharmaceutical composition achieves an effective extended release effect of moxidectin and an isoxazoline compound.
[0154] The present invention also provides a method for introducing and maintaining blood levels of moxidectin and isoxazoline compounds, particularly moxidectin and flurellana, in animals for an extended period of time; and a method for preventing or treating infections and infestations caused by helminths, nematodes, mites and endo- and ecto-parasitic arthropods in animals.
[0155] In one embodiment, moxidectin is present in the injectable veterinary composition in an amount of about 0.01% to about 1.0% by weight.
[0156] In a specific embodiment, the injectable composition of the present invention comprises 15% flurellana and 0.17% moxidectin.
[0157] The waxes and fats suitable for use in the composition of the present invention generally have a melting point above 40°C, preferably above 50°C.
[0158] The term "wax" as used herein is defined as described in Hawley's The Condensed Chemical Dictionary, 11th Edition, as a high molecular weight, low melting point organic mixture or compound that is solid at room temperature and generally similar in composition to fats and oils except that it does not contain glycerides.
[0159] Some are hydrocarbons; others are esters of fatty acids and alcohols. These compounds include saturated or unsaturated long-chain C 10 -C 24 Fatty acids, alcohols, esters, salts, ethers or mixtures thereof. They are classified as lipids. Waxes are thermoplastics, but since they are not polymers, they are not considered to be in the plastic family.
[0160] Common properties of these waxes include water resistance; smooth texture; non-toxicity; and the absence of objectionable odor and color. They are flammable and have good dielectric properties. They are soluble in most organic solvents and insoluble in water. The main types are as follows:
[0161] A. Natural
[0162] 1. Animal wax (beeswax, lanolin, shellac wax, Chinese insect wax)
[0163] 2. Vegetables (carnauba, candelilla, bayberry, sugarcane)
[0164] B. Minerals
[0165] 1. Fossil paraffin or earth wax (ozokerite, ceresin, lignite wax)
[0166] 2. Petroleum wax (paraffin, microcrystalline) (loose wax or flake wax)
[0167] D. Synthetic
[0168] 1. Olefinic polymers and polyol ether-esters ("carbon waxes")
[0169] 2. Chlorinated naphthalenes ("light waxes").
[0170] The term "fat" as used herein is defined as glycerol esters of higher fatty acids such as stearic acid and palmitic acid. Such esters and mixtures thereof are solid at room temperature and exhibit a crystalline structure. Lard and beef tallow are examples.
[0171] The term "fat" usually refers specifically to triglycerides, while "lipid" is all-inclusive.
[0172] The fats are preferably composed of triglycerides of long chain C12-C22 fatty acids, such as stearate, palmitate, laurate, myristate, arachidate and behenate, and mixtures thereof; those having a melting point greater than 50°C are most preferred.
[0173] In the practice of the present invention, tristearin is the most preferred fat.
[0174] Antioxidants suitable for use in the practice of the present invention include any antioxidant known in the art to be suitable for stabilizing moxidectin compounds.
[0175] Antioxidants of the present invention can be defined as organic compounds added to rubber, natural fats and oils, foods, gasoline and lubricants to retard oxidation, deterioration, rancidity and gum formation, respectively. Rubber antioxidants are typically aromatic amine types, such as di-,8-naphthyl-p-phenylenediamine and phenyl-,8-naphthylamine.
[0176] Many antioxidants are substituted phenolic compounds (butylated hydroxyanisole, butylated p-cresol, and propyl gallate). Food antioxidants are effective at very low concentrations and not only delay rancidity but also preserve nutritional value by minimizing the breakdown of vitamins and essential fatty acids.
[0177] The moxidectin microspheres of the present invention can be sterilized with gamma radiation or electron beam and maintain shelf life without significant loss of biological activity. Moxidectin is generally susceptible to degradation and loses most of its biological activity, especially when irradiated.
[0178] Antioxidants suitable for the microsphere composition of the present invention include tocopherol, ascorbic acid, ascorbyl palmitate, fumaric acid, malic acid, sodium ascorbate, sodium metabisulfite, n-propyl gallate, BHA (butylated hydroxyanisole), BHT (butylated hydroxytoluene) monothioglycerol, tert-butylhydroxyquinone, 6-ethoxy-1,2-dihydro-2,2,4-trimethylquinoline, etc., among which butylated hydroxytoluene is a preferred antioxidant.
[0179] In certain embodiments, the antioxidant is generally added to the formulation in an amount of about 0.01 to about 2.0%, particularly preferably about 0.05 to about 1.0%, based on the total weight of the formulation.
[0180] The microsphere compositions of the present invention can be sterilized using gamma radiation or electron beam and maintain shelf life without significant loss of biological activity.
[0181] Microspheres for use in the compositions of the present invention can be prepared by incorporating moxidectin, antioxidants and optional other excipients with molten fat, wax or mixtures thereof and then forming microspheres of the resulting mixture by various techniques (e.g. emulsifying or atomizing the mixture), or by mechanically processing the ingredients and molten fat, wax or mixtures thereof and cooling (e.g. using a centrifugal disk).
[0182] Alternatively, a mixture of the active ingredient, antioxidant, excipients and fats, waxes and mixtures thereof and oils can be cooled to give a solid which can then be processed by procedures such as milling, grinding and the like.
[0183] The stable microspheres of the present invention are dispersed in a pharmaceutically acceptable carrier to obtain a sustained-release composition for parenteral administration.
[0184] Excipients such as surfactants, salts, buffers, or mixtures thereof may be included in the vehicles of the present invention.
[0185] The amount of the excipient suitable for use in the present invention is in the range of about 0.1 wt % to 20 wt %.
[0186] Preferably, the cellulose derivative such as carboxymethylcellulose accounts for about 1-5% by weight of the carrier, and the inorganic salt such as NaCl accounts for about 0.1-2% by weight of the carrier.
[0187] Maintaining blood levels of the active compound is relevant to protecting or treating warm-blooded animals from infection and infestation by helminths, nematodes, mites and endo- and ecto-parasitic arthropods.
[0188] Maintaining blood levels is an indication of a slow release of the active ingredient.
[0189] The present invention includes the use of the compositions herein to introduce and maintain levels of moxidectin and isoxazoline compounds, particularly flurellanil, in the bloodstream of an animal.
[0190] It has been found that the injectable composition of the present invention comprising particles of an isoxazoline compound and moxidectin microspheres having a defined particle size exhibits a desired bioavailability and duration of efficacy while causing minimal irritation at the injection site.
[0191] The composition also provides the desired safety profile for warm-blooded and avian recipients.
[0192] Moreover, it has been found that a single administration of such compositions generally provides effective activity against one or more parasites (e.g., ectoparasites such as fleas, ticks or mites), while also tending to provide a rapid onset of activity, a long duration of activity and / or a desirable safety profile.
[0193] The present invention also provides a method for treating or preventing parasitic infections and infestations in animals, the method comprising administering an effective amount of an injectable composition comprising an antiparasitic effective amount of at least one isoxazoline compound and moxidectin microspheres of defined particle size and a pharmaceutically acceptable excipient.
[0194] Surprisingly, it has been found that the compositions of the invention described herein exhibit superior broad-spectrum efficacy against harmful parasites (e.g., ectoparasites, such as fleas and ticks) more rapidly and over a longer duration than other injectable compositions known in the art, while exhibiting minimal irritation at the injection site.
[0195] The pharmaceutical composition of the present invention can be administered by subcutaneous or intramuscular injection.
[0196] The long-acting injectable composition of the present invention includes a pharmaceutically acceptable excipient.
[0197] Pharmaceutically acceptable excipients include, but are not limited to, surfactants, antioxidants, preservatives, pH stabilizers (eg, buffers), and other inactive excipients.
[0198] In another embodiment, the compositions of the present invention may comprise from about 0.01% to about 20% (w / v) of a pharmaceutically acceptable excipient.
[0199] In other embodiments, the composition may include about 0.01% to about 5% (w / v), about 0.1% to about 10% (w / v), or about 0.1% to about 5% (w / v) of a pharmaceutically acceptable excipient. In other embodiments, the composition may include about 5 to about 15% (w / v), or about 5 to about 10% (w / v) of a pharmaceutically acceptable excipient.
[0200] In another embodiment, the composition may comprise from about 7 to about 10% of a pharmaceutically acceptable excipient.
[0201] The surfactant may be present in the compositions of the present invention at a concentration of about 0.1% to about 10% (w / w), about 1% to about 10% (w / w), or about 5% to about 10% (w / w). More typically, the surfactant may be present at a concentration of about 0.1% to about 5% (w / w), or about 1 to about 5% (w / w).
[0202] Examples of surfactants that can be used in the composition include, but are not limited to, glyceryl monooleate, polyoxyethylene sorbitan fatty acid esters, sorbitan esters (including sorbitan monooleate), ), polyvinyl alcohol, polysorbates (including polysorbate 20 and polysorbate 80), D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS), sodium lauryl sulfate, copolymers of ethylene oxide and propylene oxide (e.g., poloxamers, such as F87, etc.), polyethylene glycol castor oil derivatives (including polyoxyethylene 35 castor oil Polyoxyethylene 40 hydrogenated castor oil ( 40), Polyoxyethylene 60 hydrogenated castor oil ); Propylene glycol monolaurate Glycerides, including glyceryl caprylate / caprate Polyglycolyzed glycerides ( PEG 300 Caprylic / Capric Glycerides PEG 400 Caprylic / Capric Glycerides PEG 300 Oleic Acid Glyceryl PEG 300 Linoleic Acid Glycerides Polyethylene glycol stearates and polyethylene glycol hydroxystearates, including polyethylene glycol 8 stearate (PEG 400 monostearate), polyethylene glycol 40 stearate (PEG 1750 monostearate, etc.).
[0203] Polyethylene glycol stearates (synonyms include macrogol stearates, polyoxyethylene stearates, polyoxyethylene stearates, ethoxylated stearates; CAS No. 9004-99-3, 9005-08-7) are mixtures of monostearate and distearate esters of mixed polyoxyethylene polymers. Polyethylene glycol hydroxystearate is a mixture of monoesters and diesters of hydroxystearic acid and polyethylene glycol. One polyethylene glycol hydroxystearate that can be used in the composition is polyethylene glycol 12-hydroxystearate. In another embodiment, the composition of the present invention may include the surfactant polyethylene glycol 15 12-hydroxystearate (from BASF 15), a mixture of monoesters and diesters of 12-hydroxystearic acid with 15 mol of ethylene oxide.
[0204] Again, these compounds and their amounts are well known in the art.
[0205] In another embodiment of the present invention, the composition of the present invention may include polyoxyethylene 35 castor oil As a surfactant. In other embodiments, the composition of the present invention may include polyoxyethylene 40 hydrogenated castor oil ( 40) or polyoxyethylene 60 hydrogenated castor oil as a surfactant. The composition of the present invention may also include a combination of surfactants.
[0206] The compositions of the present invention may contain other inert ingredients such as antioxidants, preservatives or pH stabilizers. These compounds are well known in the composition art.
[0207] Antioxidants such as vitamin E, α-tocopherol, ascorbic acid, ascorbyl palmitate, citric acid, fumaric acid, malic acid, sodium ascorbate, sodium metabisulfite, sodium metabisulfite, n-propyl gallate, BHA (butylated hydroxyanisole), BHT (butylated hydroxytoluene), BHA and citric acid, monothioglycerol, tert-butylhydroquinone (TBHQ), benzyl alcohol, etc. can be added to the composition of the present invention.
[0208] Based on the total weight (w / w) of the composition, the antioxidant is generally included in the composition of the present invention in an amount of about 0.01% to about 3%, or about 0.01% to about 2% (w / v). In another embodiment, the composition comprises about 0.05% to about 1.0% (w / w) of an antioxidant or a mixture thereof.
[0209] The suitable amount of preservatives such as benzyl alcohol in the composition is about 0.01-about 10.0%, particularly preferably about 0.05-about 5.0%. Other preservatives include parabens (methyl paraben and / or propyl paraben), benzalkonium chloride, benzethonium chloride, benzoic acid, benzyl alcohol, bronopol, butyl paraben, cetyl trimethylammonium bromide, chlorhexidine, chlorobutanol, chlorocresol, cresol, ethyl paraben, imidurea, methyl paraben, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric borate, phenylmercuric nitrate, potassium sorbate, sodium benzoate, sodium propionate, sorbic acid, thimerosal, etc.
[0210] Preferred ranges for these compounds include from about 0.01 to about 5%.
[0211] Benzyl alcohol is preferred.
[0212] Compounds that stabilize the pH of the composition may also be present. Again, these compounds and how to use them are well known to those skilled in the art. Buffer systems include, for example, systems selected from the group consisting of acetic acid / acetate, malic acid / malate, citric acid / citrate, tartaric acid / tartrate, lactic acid / lactate, phosphoric acid / phosphate, glycine / glycidate, tris, glutamic acid / glutamate and sodium carbonate, in particular sodium phosphate or sodium citrate.
[0213] Aqueous suspensions may contain isoxazoline compound particles as described herein and moxidectin microspheres mixed with excipients suitable for the manufacture of aqueous suspensions.
[0214] Such excipients include suspending agents, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum arabic; dispersing or wetting agents include naturally occurring phosphatides, for example, lecithin, or condensation products of alkylene oxides with fatty acids, for example, polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example, heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol, for example, polyoxyethylene sorbitan monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example, polyethylene sorbitan monooleate.
[0215] Aqueous suspensions may also contain one or more preservatives, for example ethyl or n-propyl p-hydroxybenzoate.
[0216] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water may provide the isoxazoline compound and moxidectin microspheres in admixture with a dispersing or wetting agent, a suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above.
[0217] In one embodiment, the isoxazoline compound is suspended in an aqueous suspension wherein the liquid carrier (diluent) is water.
[0218] In another embodiment, the liquid carrier (diluent) for the aqueous suspension comprises water and a co-solvent.
[0219] The co-solvent that can be used in the injectable composition of the present invention comprising the isoxazoline compound and the moxidectin microspheres can be a single co-solvent or a blend of co-solvents.
[0220] In one embodiment, the co-solvent used in the aqueous injectable composition of the present invention comprises a polar solvent that is miscible with water.
[0221] Non-limiting examples of these co-solvents include ethanol, isopropanol, benzyl alcohol, glycol ethers (e.g., including but not limited to diethylene glycol monoethyl ether (DGME, The solvents may be selected from the group consisting of butyl diglycol, dipropylene glycol n-butyl ether, ethylene glycol monoethyl ether, ethylene glycol monomethyl ether, dipropylene glycol monomethyl ether, propylene glycol monomethyl ether, propylene glycol monoethyl ether, etc.), liquid polyethylene glycols (PEGs) (e.g., PEG 400), propylene glycol, carbonates (e.g., propylene carbonate), 2-pyrrolidone, N-methylpyrrolidone, dimethyl isosorbide (DMI), dimethylacetamide, dimethyl sulfoxide, glycerol formal, or a mixture of at least two of these solvents.
[0222] In one embodiment, the composition of the present invention comprises a polar protic solvent, including but not limited to alcohols such as ethanol, isopropanol or glycols or glycol ethers. In another embodiment, the long-acting injectable composition of the present invention comprises a polar aprotic solvent, such as N-methylpyrrolidone, dimethyl isosorbide, dimethylacetamide, dimethyl sulfoxide or propylene carbonate.
[0223] In one embodiment, the isoxazoline compounds may exist in various isomeric forms. References to isoxazoline compounds always include all possible isomeric forms of such compounds.
[0224] Unless otherwise noted, compound structures that do not indicate a specific conformation are intended to encompass compositions of all possible conformational isomers of the compound, as well as compositions containing less than all possible conformational isomers. In some embodiments, the compound is a chiral compound.
[0225] Particularly preferred is the (S) enantiomer. In some embodiments, the compound is an achiral compound.
[0226] In one embodiment, the isoxazoline compounds of formula (I) can be prepared according to, for example, patent applications US 2007 / 0066617, WO 2007 / 079162, WO 2009 / 002809, WO 2009 / 080250, WO 2010 / 070068, WO 2010 / 079077, 2011 / 075591 and WO 2011 / 124998 or any other method within the capabilities of a skilled person who is an expert in chemical synthesis.
[0227] For the chemical preparation of the products of the invention, the person skilled in the art is deemed to have inter alia the entire content of "Chemical Abstracts" and the documents cited therein.
[0228] In one embodiment, the isoxazoline compound is suspended in the composition. In one embodiment, the suspension is aqueous. In an alternative embodiment, the suspension is non-aqueous.
[0229] In one embodiment, the pharmaceutical composition is substantially free of organic solvents.
[0230] In one embodiment, the pharmaceutical composition comprises a surfactant / wetting agent. In another embodiment, the surfactant / wetting agent is a poloxamer.
[0231] Alternatives to poloxamers are other water-soluble / miscible nonionic surfactants, including sorbitan fatty acid esters (Spans), polyoxyethylene sorbitan fatty acid esters (polysorbates / Tweens), polyoxyethylene polyoxyethylene castor oil derivatives (Cremaphors), polyoxyethylene stearates, lecithin, and TPGS (d-α-tocopheryl polyethylene glycol 1000 succinate).
[0232] The surfactant / wetting agent is present in the composition in an amount of about 0.01% w / v to about 0.5% w / v or about 0.05% w / v to about 0.1% w / v.
[0233] Poloxamers are nonionic triblock copolymers of polyoxyethylene (poly(ethylene oxide)) consisting of a central hydrophobic chain of polyoxypropylene (polypropylene oxide) flanked by two hydrophilic chains (see US Pat. No. 3,740,421).
[0234] Poloxamer 124 is poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol), CAS No. 9003-11-6, also known as Lutrol L44 or Kollisolv P124.
[0235] Lutrol F68 is another poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol), also known as Poloxamer 188 or Kolliphor P188.
[0236] In one embodiment, the pharmaceutical composition comprises a suspending agent. In one embodiment, the suspending agent is carboxymethylcellulose, especially sodium carboxymethylcellulose (NaCMC).
[0237] In an alternative embodiment, the suspending agent is methylcellulose or polyvinylpyrrolidone.
[0238] In one embodiment, the pharmaceutical composition comprises a preservative. In one embodiment, the preservative is benzyl alcohol.
[0239] In an alternative embodiment, the preservative is m-cresol, benzalkonium chloride, methylparaben, or propylparaben.
[0240] Injectable pharmaceutical compositions can be prepared by combining and mixing solid components and then suspending the solid mixture in a diluent.
[0241] The method for preparing an injectable pharmaceutical composition comprises combining the isoxazoline particles with the moxidectin microspheres to form a solid mixture which is reconstituted with an aqueous liquid carrier in a subsequent step to form an aqueous suspension ready for injection.
[0242] In one embodiment, the aqueous liquid carrier is water.
[0243] In an alternative embodiment, the diluent is an oil or solvent that has little or no solubility for the isoxazoline compound and the moxidectin microsphere components.
[0244] The pharmaceutical composition also comprises a surfactant / wetting agent.
[0245] Specific surfactants / wetting agents and alternatives to surfactants / wetting agents are discussed throughout the specification and examples.
[0246] Pharmaceutical compositions may also contain additional excipients, such as suspending agents or preservatives.
[0247] Specific examples of suitable excipients and replacement agents are in the description and examples discussed below in this application.
[0248] Particle size and measurement of isoxazoline compound granules and moxidectin microspheres
[0249] It has been found that the injectable compositions of the present invention comprising particles of an isoxazoline compound having a defined particle size have particularly beneficial properties.
[0250] In one embodiment, the moxidectin microspheres and the isoxazoline compound particles have the same particle size.
[0251] Therefore, in this specification, reference to "isoxazoline compound particle size" includes reference to compositions wherein the moxidectin microspheres have the same particle size and are measured by the same method.
[0252] In one embodiment, the isoxazoline compound and / or moxidectin microspheres have a D50 particle size distribution of about 25 microns to about 250 microns, a particle size of about 11 microns to about 250 microns, a particle size of about 50 microns to about 150 microns, a particle size of about 75 microns to about 130 microns, a particle size of about 90 microns to about 110 microns, and a particle size of about 30 microns to about 100 microns as measured by a static light scattering instrument.
[0253] Particle size distribution describes the relative amounts of particles present according to size.
[0254] D10 is the particle size distribution representing the size below which 10% of the particles are smaller.
[0255] D50 is a particle size measurement distribution that represents the size that 50% of the particles are smaller than.
[0256] D90 is a particle size measurement distribution that represents the size that 90% of the particles are smaller than.
[0257] In another embodiment, the particle sizes are different.
[0258] In one embodiment, the particle sizes of the isoxazoline compound and the moxidectin microspheres are in a similar range.
[0259] In another embodiment, the particle size is not within a similar range.
[0260] In a specific embodiment, the isoxazoline compound has a particle size D10 greater than 10 μm, a particle size D50 of 80-120 μm, and a particle size D90 less than 210 μm.
[0261] In a specific embodiment, for moxidectin microspheres, the D10 of the particle size is greater than 50 μm, the D50 of the particle size is 100 to 150 μm, and the D90 of the particle size is less than 200 μm.
[0262] In a specific embodiment, the particle size D10 is about 10 μm, about 20 μm, about 30 μm, about 40 μm, about 50 μm, about 60 μm, or about 80 μm.
[0263] In a specific embodiment, the moxidectin microspheres have a particle size D10 of about 80 μm.
[0264] In a specific embodiment, the particle size D50 is about 50 μm, about 75 μm, about 80 μm, about 90 μm, about 100 μm, about 110 μm, about 120 μm, about 130 μm, about 140 μm, or about 150 μm.
[0265] In a specific embodiment, the moxidectin microspheres have a particle size D50 of about 110 μm.
[0266] In a specific embodiment, the particle size has a D90 of about 100 μm, about 130 μm, about 150 μm, about 175 μm, about 200 μm, or about 250 μm.
[0267] In a specific embodiment, the isoxazoline compound has a particle size D10 of about 20-35 μm, a particle size D50 of about 90-105 μm and a particle size D90 of about 155-175 μm.
[0268] In a specific embodiment, for moxidectin microspheres, the D10 of the particle size is about 60 to 85 μm, the D50 of the particle size is about 90 to 115 μm, and the D90 of the particle size is about 145 to 165 μm.
[0269] In a specific embodiment, for moxidectin microspheres, the D10 of the particle size is about 80 μm, the D50 of the particle size is about 110 μm, and the D90 of the particle size is about 150 μm.
[0270] In a specific embodiment, the D10 of the particle size is about 25 to 30 μm, the D50 of the particle size is about 95 to 100 μm, and the D90 of the particle size is about 160 to 170 μm.
[0271] In a specific embodiment, the D10 of the particle size is about 10 to 20 μm, the D50 of the particle size is about 85 to 110 μm, and the D90 of the particle size is about 170 to 185 μm.
[0272] In a specific embodiment, the D10 of the particle size is about 10 to 15 μm, the D50 of the particle size is about 95 to 105 μm, and the D90 of the particle size is about 175 to 180 μm.
[0273] In a specific embodiment, the particle size D10 is about 10 to 25 μm, the particle size D50 is about 40 to 60 μm, and the particle size D90 is about 95 to 100 μm.
[0274] In a specific embodiment, the D10 of the particle size is about 15 to 20 μm, the D50 of the particle size is about 45 to 55 μm, and the D90 of the particle size is about 90 to 95 μm.
[0275] In a specific embodiment, the D10 of the particle size is about 30 to 50 μm, and the D50 of the particle size is about 70 to 130 μm.
[0276] In a specific embodiment, the particle size D10 is about 35 to 45 μm, and the particle size D50 is about 90 to 110 μm.
[0277] In a specific embodiment, the D10 of the particle size is about 40 μm and the D50 of the particle size is about 100 μm.
[0278] Volume weighted particle size can be measured by sieving, microscopy or laser diffraction (Malvern or Sympatec).
[0279] Volume weighted particle size measurements can be made with a Malvern Mastersizer 2000 with a Hydro 2000G measuring cell or with a Horiba LA-910 laser scattering particle size distribution analyzer. Volume weighted particle size can be measured by a Sympatec Helos instrument.
[0280] For use in the present invention, the isoxazoline compound is present in the pharmaceutical composition according to the present invention in an amount of about 0.1 to about 50% w / v of the final pharmaceutical composition according to the present invention.
[0281] The isoxazoline is present in an amount of about 10 to about 45% w / v; about 20 and about 45% w / v; about 15 and 35% w / v or about 25% w / v and about 35% w / v or about 1% w / v and about 12% w / v or about 3% w / v and about 9% w / v of the pharmaceutical composition of the present invention.
[0282] In an embodiment of the present invention and / or its embodiments, the composition comprises eprinomectin as (a1) physiologically active macrolide and flurellan, preferably (S)-flurellan, as (b) isoxazoline compound of formula (I).
[0283] In an embodiment of the present invention and / or its embodiments, the composition comprises milbemycin oxime as (a) physiologically active macrolide and flurellan, preferably (S)-flurellan, as (b) isoxazoline compound of formula (I).
[0284] In an embodiment of the present invention and / or its embodiments, the composition comprises selamectin as (a) physiologically active macrolide and flurellan, preferably (S)-flurellan, as (b) isoxazoline compound of formula (I).
[0285] In an embodiment of the present invention and / or its embodiments, the composition comprises moxidectin as (a) physiologically active macrolide and afoxolamide, preferably (S)-fluramide, as (b) isoxazoline compound of formula (I).
[0286] In an embodiment of the present invention and / or its embodiments, the composition comprises eprinomectin as (a) a physiologically active macrolide and afoxolamide, preferably (S)-afoxolamide, as (b) an isoxazoline compound of formula (I).
[0287] In an embodiment of the present invention and / or its embodiments, the composition comprises milbemycin oxime as (a) physiologically active macrolide and afoxolamide, preferably (S)-afoxolamide, as (b) isoxazoline compound of formula (I).
[0288] In an embodiment of the present invention and / or its embodiments, the composition comprises selamectin as (a) physiologically active macrolide and afoxolane, preferably (S)-afoxolane, as (b) isoxazoline compound of formula (I).
[0289] In an embodiment of the present invention and / or its embodiments, the composition comprises moxidectin as (a) physiologically active macrolide and afoxolane, preferably (S)-afoxolane, as (b) isoxazoline compound of formula (I).
[0290] In an embodiment of the present invention and / or its embodiments, the composition comprises eprinomectin as (a) a physiologically active macrolide and sarolidine as (b) an isoxazoline compound of formula (I).
[0291] In an embodiment of the present invention and / or its embodiments, the composition comprises milbemycin oxime as the physiologically active macrolide and sarolidine as (b) the isoxazoline compound of formula (I).
[0292] In an embodiment of the present invention and / or its embodiments, the composition comprises selamectin as the physiologically active macrolide and sarolanil as (b) the isoxazoline compound of formula (I).
[0293] In an embodiment of the present invention and / or its embodiments, the composition comprises moxidectin as the physiologically active macrolide and sarolanil as (b) the isoxazoline compound of formula (I).
[0294] In an embodiment of the present invention and / or its embodiments, the composition comprises eprinomectin as the physiologically active macrolide and lotiranab as (b) the isoxazoline compound of formula (I).
[0295] In an embodiment of the present invention and / or its embodiments, the composition comprises milbemycin oxime as the physiologically active macrolide and lotiranab as (b) the isoxazoline compound of formula (I).
[0296] In an embodiment of the present invention and / or its embodiments, the composition comprises selamectin as the physiologically active macrolide and lotiranab as (b) the isoxazoline compound of formula (I).
[0297] In an embodiment of the present invention and / or its embodiments, the composition comprises moxidectin as the physiologically active macrolide and lotiranab as (b) the isoxazoline compound of formula (I).
[0298] Injectable compositions generally require sterilization prior to administration to animals.In preferred embodiments of the invention and / or its embodiments, the microspheres are sterilized, for example by gamma radiation or electron beam irradiation.
[0299] Although physiologically active macrolides have been reported to degrade and lose most of their bioactivity upon irradiation, microspheres (a) can be sterilized by irradiation for injection without negatively affecting the stability of the active ingredient.
[0300] In one embodiment, the amount of the isoxazoline compound in the pharmaceutical composition according to the present invention is about 30% w / v of the pharmaceutical composition according to the present invention.
[0301] In one embodiment, the amount of the isoxazoline compound in the pharmaceutical composition according to the present invention is about 7.5% w / v of the pharmaceutical composition according to the present invention.
[0302] In one embodiment, the pharmaceutical composition must be reconstituted prior to injection. For example, the pharmaceutical composition is reconstituted in an aqueous liquid carrier prior to injection.
[0303] In another embodiment, the pharmaceutical composition is a ready-to-use composition ready for injection.
[0304] In one embodiment, the pharmaceutical composition is administered in combination with an additional therapeutic agent.
[0305] Administration of the additional therapeutic agent can be in the same composition or in a separate composition.
[0306] The additional therapeutic agent may be a parasiticide or a vaccine.
[0307] In another embodiment, the additional therapeutic agent is another parasiticide. The other active ingredients are selected from isoxazoline compounds, macrolides, avermectins (e.g., ivermectin, selamectin, doramectin, abamectin and eprinomectin); milbemycins (milbemycin oxime); pro-benzimidazoles (e.g., febantel, netobimin and thiophanate); benzimidazole derivatives, such as thiazole benzimidazole derivatives (e.g., thiabendazole and cambendazole), carbamate benzimidazole derivatives (e.g., fenbendazole, albendazole (oxide), mebendazole, oxfendazole, parbendazole, oxibendazole, flubendazole and triclabendazole); imidazothiazoles (e.g., levamisole); and tetramisole); tetrahydropyrimidines (morantel and pyrantel), salicylanilides (e.g., closantel, oxyclozanide, rafoxanide and niclosamide); nitrophenolic compounds (e.g., nitrosyl and nitrosocyanate); benzene disulfonamides (e.g., clorsulon); pyrazinoisoquinolines (e.g., praziquantel and iprotel); heterocyclic compounds (e.g., piperazine, diethylcarbamazine and phenothiazines); dichlorophen, arsenides (e.g., thioacetyltartaric acid amide, meloxamine and arsenamide); cyclooctadepsipeptides (e.g., emodepside); paraherquamides (e.g., derquantel); and aminoacetonitrile compounds (e.g., monatel, AAD 1566); amidine compounds (e.g., amitrail and tripenamide), including all pharmaceutically acceptable forms, such as salts, solvates or N-oxides.
[0308] One embodiment of the present invention is a method for treating or preventing parasitic infections in animals, which comprises administering an effective amount of the above-mentioned injectable pharmaceutical composition to an animal in need thereof.
[0309] In one embodiment, the animal suffers minimal injection site irritation.
[0310] As stated above, minimal injection site irritation means injection site irritation of less than 2 x 2 cm that persists for less than 2 to 3 days.
[0311] In one embodiment, the animal is a companion animal. In one embodiment, the companion animal is a dog or a cat.
[0312] Of course, the best effective amount employed to obtain optimal results will depend upon the particular isoxazoline compound employed, the species of animal being treated, and the type and severity of the parasitic infection or infestation.
[0313] When an isoxazoline compound of formula (I) is used, good results are generally obtained administering about 0.01 to 200 mg / kg animal body weight, and in one embodiment 0.1 to 100 mg / kg animal body weight, or 0.5 to 50 mg / kg animal body weight, or 1 to 30 mg / kg animal body weight, such total dose being given once or in divided doses.
[0314] Good results are generally obtained when moxidectin is administered at about 0.01 to 10 mg / kg, and in one embodiment 0.1 to 5 mg / kg, body weight of the animal, such total dose being given once or in divided doses.
[0315] The injectable pharmaceutical composition may be administered daily, weekly, monthly, semi-annually or yearly.
[0316] The injectable pharmaceutical composition can be administered every month, every two months, every three months, every four months, every five months, every six months, every seven months, every eight months, every nine months, every ten months, every eleven months, every twelve months, every 13 months, every 14 months, every 15 months, every 16 months, every 17 months, or every 18 months.
[0317] Particularly preferred is administration once every 6 months.
[0318] It is also preferred to apply once every 12 months. This provides long-term protection to the animal from ectoparasites (particularly fleas and ticks) and endoparasites (particularly heartworms and / or gastrointestinal worms). Particularly preferred is long-term protection against heartworm infestation.
[0319] The injectable composition of the present invention may be advantageously used in conjunction with annual vaccinations against infectious diseases such as distemper, influenza, rabies and other vaccines with conventional antigens.
[0320] In one embodiment of the injectable pharmaceutical composition, the isoxazoline compound and / or moxidectin microspheres have a particle size D50 of about 75 microns to about 130 microns and a particle size D10 of about 30 microns to about 100 microns.
[0321] One embodiment of the invention is a kit for treating or preventing parasitic infestations in animals, the kit comprising two or more containers:
[0322] a) solid crystalline isoxazoline compound and moxidectin microspheres;
[0323] b) a vehicle comprising a pharmaceutically acceptable excipient capable of forming a suspension with the compound of a); and
[0324] c) instructions for combining the solid crystalline isoxazoline compound and moxidectin microspheres with an aqueous liquid carrier prior to injection.
[0325] For the solid crystalline isoxazoline compound and moxidectin microspheres, the D50 of the particle size is about 75 microns to about 130 microns, and the D10 of the particle size is about 30 microns to about 50 microns.
[0326] In another embodiment, the isoxazoline compound is flurellanil.
[0327] One embodiment of the present invention is a kit, wherein the kit comprises:
[0328] a) a first container comprising a solid mixture of particles of an isoxazoline compound of formula (I) as described in claims 1, 8, 9, 10, 11, 12, 17 and 18 and moxidectin microspheres as described in claims 1 to 12, and;
[0329] b) a second container having an aqueous carrier comprising one or more suspending agents, wetting agents and / or preservatives and water; and
[0330] c) instructions for reconstituting the moxidectin microspheres and isoxazoline compound particles with an aqueous carrier prior to subcutaneous or intramuscular injection into an animal.
[0331] In one embodiment, the first container comprises effective amounts of moxidectin and an isoxazoline compound of formula (I) as described above, sufficient to treat and / or prevent parasitic infestations in animals.
[0332] In one embodiment, the kit further comprises means for reconstitution and parenteral administration (by injection) of the mixture of the compositions from the first and second containers to an animal, particularly using a syringe (eg, 18 gauge).
[0333] In one embodiment, the isoxazoline compound of formula (I) and moxidectin microspheres in the first container have a volume weighted particle size distribution D50 of about 25 microns to about 250 microns as measured by a static light scattering instrument.
[0334] In another embodiment, the isoxazoline compound has a particle size D10 of about 20-35 mm, a particle size D50 of about 90-105 mm and a particle size D90 of about 155-175 mm in the first container.
[0335] Another aspect of the present invention is a method of treating or preventing a parasitic infection in an animal comprising administering an injectable veterinary composition to an animal in need thereof.
[0336] Another aspect of the present invention is a method for preparing an injectable veterinary composition according to the present invention, comprising the following steps:
[0337] a) preparing isoxazoline compound particles by crystallization;
[0338] b) preparing moxidectin microspheres by melting fat, wax or a mixture thereof and adding moxidectin and optionally an antioxidant, and preparing microspheres by spinning disk atomization and sieving;
[0339] c) filling the moxidectin microspheres obtained in step b) and the isoxazoline particles obtained in step a) into a first container;
[0340] d) preparing an aqueous carrier by dissolving excipients including a suspending agent, a wetting agent and / or a preservative in water and filling into a second container;
[0341] e) reconstitute the solid by transferring the aqueous carrier from the second container d) to the first container c) and shake to form a.
[0342] The spinning disk is considered to be a production technology that produces uniform spherical particles with a small particle size distribution span by controlling key process parameters such as melt temperature, flow rate and disk speed.
[0343] The spinning disk method is an encapsulation technique that uses mechanical energy to pressurize or increase the kinetic energy of a liquid film to potentially disintegrate it in droplet form.
[0344] Alternatively, moxidectin may be uniformly incorporated into fats, waxes or mixtures thereof using other methods such as hot melt extrusion, hot melt granulation, thin film evaporation, etc. The resulting mixture may be ground or sprayed to achieve the desired particle size.
[0345] If desired, screening of the material may be performed to prepare batches of defined particle size.
[0346] In other words, the microspheres (a) can be considered as microspheres prepared by incorporating the physiologically active macrolide and then forming microspheres of the resulting mixture by various techniques as described above.
[0347] Alternatively, the mixture of the physiologically active macrolide and optional other excipients may be cooled to obtain a solid which may then be processed by procedures such as milling, grinding, and the like.
[0348] In general, solvent evaporation, spinning disk atomization, spray drying and sieving are methods known to those skilled in the art.
[0349] In one embodiment of the present invention and / or its embodiments, the mixture in the first container comprises an effective amount of microspheres as described in any one of claims 1 to 14 and particles of an isoxazoline compound of formula (I) as described in any one of claims 1 to 14 and / or a compound of formula (II) as described in any one of claims 1 to 14, which is sufficient to treat or prevent parasitic infestations in animals.
[0350] In one embodiment of the invention and / or its embodiments, the kit further comprises means for reconstitution and parenteral administration of the mixture of the compositions from the first and second containers to an animal, in particular a syringe.
[0351] Another embodiment is a method of treating and / or preventing parasitic infestations in animals over an extended period of 6 months or alternatively 12 months, the method comprising administering to an animal in need thereof a reconstituted liquid prepared when using a kit as described above and administering it to the animal by injection according to the instructions.
[0352] Parasites are ectoparasites and endoparasites as described above.
[0353] Preferred target animals are companion animals, such as cats or dogs, particularly dogs.
[0354] Of course, the optimum effective amount employed to obtain optimal results will depend upon the particular isoxazoline compound and physiologically active macrolide employed, the animal species to be treated, and the type and severity of the parasitic infection or infestation.
[0355] In a preferred embodiment of the present invention and / or its embodiments, the isoxazoline compound of formula (I), preferably flurellana, is administered at about 0.01 to about 200 mg / kg animal body weight, preferably about 0.1 to about 100 mg / kg animal body weight, more preferably about 0.5 to about 50 mg / kg animal body weight, and in particular about 1 to about 30 mg / kg animal body weight. The total dose can be administered once or in divided doses.
[0356] In a preferred embodiment of the present invention and / or its embodiments, the physiologically active macrolide, preferably moxidectin, is administered at about 0.01 to about 10 mg / kg animal body weight, preferably about 0.1 to about 5 mg / kg animal body weight. The total dose may be administered once or in divided doses.
[0357] The results show that when the injectable veterinary composition of the present invention is used to treat and / or prevent parasitic infestations in animals, the treated animals experience minimal injection site irritation.
[0358] As stated above, minimal injection site irritation means injection site irritation of less than 2 x 2 cm that persists for less than 2 to 3 days.
[0359] Another aspect of the invention is a method for treating and / or preventing parasitic infections in animals, comprising administering to a subject in need thereof a therapeutically effective amount of an injectable veterinary composition according to the invention or a kit according to the invention.
[0360] Likewise, with regard to injectable veterinary compositions and kits, the above also applies. The same applies to parasites and parasitic infestations.
[0361] Features of the present invention have been described in the embodiments of the present application; however, for the sake of brevity, not all combinations of features are literally described.
[0362] However, the combination of features described above is expressly considered to be part of the present invention. Example
[0363] Example 1: Preparation of 10% moxidectin microspheres
[0364] 10% moxidectin in tristearin (GTS) microspheres were prepared by spinning disk with the following formulation:
[0365] Table 1: Example Formulations of 10% Moxidectin in Tristearin Microspheres
[0366] Ingredients %w / w Moxidectin 10.00 Glyceryl Tristearate 89.97 Butylated Hydroxytoluene 0.03
[0367] Briefly, 180 g of tristearin was melted in a container and heated to a temperature of 180°C with stirring. 20 g of moxidectin and 0.06 g of butylated hydroxytoluene were added and stirred until dissolved. The resulting molten solution was cooled to ~80°C and pumped onto a 4" tray heated to ~90°C at 3000 rpm. The resulting microspheres were sieved and material less than 150 μm was collected for further characterization and investigation.
[0368] Example 2
[0369] Sterilization of 10% moxidectin in GTS microspheres - Stability of microspheres to irradiation
[0370] The microsphere compositions listed below were placed in 20 mL serum vials, two of which were flushed with dry nitrogen to remove oxygen. The vials were then closed with elastomeric septa and crimped aluminum caps. Next, the microspheres were irradiated to 15, 20, and 25 kGy by both gamma radiation and electron beam for sterilization. The microspheres were extracted into acetonitrile / water (1: 1) and analyzed by high performance liquid chromatography for 23-(O-methyloxime)-F28249a. The results of this experiment are summarized in Table 2 below. GTS microspheres were sterilized at low or room temperature with or without nitrogen blanketing.
[0371] The samples were evaluated for assay variation. % assay is % of the non-irradiated assay.
[0372] Table 2: Effects of irradiation type, irradiation dose, temperature and nitrogen blanket on moxidectin determination during sterilization
[0373]
[0374] Example 3: Preparation of liquid aqueous carrier
[0375] About 50% of the water for injection is placed in a container and heated to about 70-80°C, and the suspending agent NaCMC, Hydroxypropyl methylcellulose E50 or PVP is added and homogenized until dissolved. The other ingredients are slowly added and mixed under stirring to achieve dispersion. Remove the heat and add cold water for injection to a volume of 10 liters. In Examples 3B and 3D, the pH is adjusted to 4.5-5.5 by adding HCl.
[0376] Each vehicle was sterilized by autoclave, and the vehicle solutions were stored in sterile containers.
[0377] Dose Uniformity for Ready-to-Use Injectable Suspension Products
[0378] Although moxidectin microspheres and fluranabol particles showed similar particle sizes, their densities were different. Therefore, many different vehicles were tested to find one suitable for uniform resuspension and administration.
[0379] Samples containing 15% flurella and 1.7% moxidectin GTS microspheres were shaken by hand until visually dispersed in each vehicle, -30 seconds.
[0380] The following vehicles were studied:
[0381] Example Formulations of Viscous Aqueous Vehicles for Reconstitution / Resuspension:
[0382] Example 3A
[0383]
[0384] Example 3B
[0385]
[0386] Example 3C
[0387]
[0388] Example 3D
[0389]
[0390] Example 3E
[0391]
[0392] Six 1 mL samples were then drawn and assayed for moxidectin and flurellanine, the results of which are shown in Table 4 below:
[0393] Table 4
[0394]
[0395]
[0396] Example 4: Preparation and use of final formulation
[0397] When used, the vehicle prepared in Example 3 is added to the moxidectin microspheres and crystalline flurellana particles prepared in Example 1, and the container is shaken to disperse the microspheres and flurellana particles in the liquid vehicle. The formulation is then drawn into a syringe at a dose volume specified for the weight of the dog to be treated and injected subcutaneously.
[0398] Example 5
[0399] Pharmacokinetic evaluation of an injectable formulation containing GTS moxidectin microspheres and flurellanine particles
[0400] preparation:
[0401] A. 15% flurellana + 0.17% moxidectin microspheres (unscreened, GTS, 25 kGy)
[0402] B. 15% Flurella + 0.17% Moxidectin Microspheres (unscreened, GTS, 15 kGy)
[0403] C. 15% flurellana + 0.17% moxidectin microspheres (D50 = 75 μm, GTS, 25 kGy)
[0404] D. 15% flurellana + 0.17% moxidectin microspheres (D50 = 150 μm, GTS, 25 kGy)
[0405] The formulation was prepared using the following method:
[0406] A. Medium
[0407] 1. Inject ~80% of the total volume with water.
[0408] 2. Add the suspending agent (sodium carboxymethylcellulose (CMCNa)) and mix with an overhead mixer for about 5 minutes.
[0409] 3. The mixture was further mixed with a homogenizer until free of agglomerates.
[0410] 4. Add wetting agent (Poloxamer 124) and mix with overhead mixer until uniform.
[0411] 5. Add preservative (benzyl alcohol (BA)) and mix with overhead mixer until uniform.
[0412] 6. Add the sodium phosphate and mix with an overhead mixer until smooth.
[0413] 7. Gently mix the antifoam (simethicone) with an overhead mixer until homogeneous (5 minutes).
[0414] 8. Adjust the pH of the mixture to pH 7.0-7.4 by adding HCl. Mix gently with an overhead mixer until homogenous (5 minutes).
[0415] 9. Add qs water to final weight for injection and mix gently with overhead mixer until homogeneous (5 minutes).
[0416] 10. The resulting preparation is packaged into injectable vials and sealed with stoppers.
[0417] 11. Autoclave the vials at 121°C for a 15 minute cycle.
[0418] B. Active ingredients
[0419] 1. Add solid flurellana and moxidectin GTS microspheres (prepared as described above) to a vial and seal.
[0420] 2. The vials are terminally sterilized by gamma irradiation.
[0421] C. Formulation of Reconstituted Injectable Formulations
[0422] 1. Add the vehicle from vial A to the active ingredient vial from B and shake.
[0423] 2. The resulting suspension is ready for injection.
[0424] A similar procedure was used to prepare the formulations of Examples 5B-H. The batch sizes ranged from 50 ml to 1000 mL.
[0425] Vehicle for all formulations:
[0426]
[0427] Samples of Formulation A, B, C, or D were administered subcutaneously as a single dose at 0.1 mL / kg BW (ie, 15 mg fluralan / kg BW, 0.17 mg moxidectin / kg BW) to different groups of eight beagle dogs per group.
[0428] The local tolerance of the formulations was evaluated for at least 21 days after application.
[0429] Blood samples for determination of moxidectin and total flurellanine plasma concentrations were collected before treatment, 8 h, and 1, 3, 5, 7, 10, 14, 21, 28, 35, 42, 49, 56, 70, 84, 98, 112, 126, 140, 154, 168, and 182 days after treatment.
[0430] Favorable pharmacokinetic profiles showing prolonged plasma levels of moxidectin and flurellanal in dogs following sc administration were obtained for all formulations tested.
[0431] There were no significant injection reactions during evaluation of the Example 5 formulation.
Claims
1. A kit comprising two or more containers, characterized in that The kit comprises: a) a first container containing a solid mixture of a) moxidectin microspheres comprising 50 to 99 wt% of fat, wax or a mixture thereof, and 0.01 to 10 wt% of an antioxidant; and b) particles of an isoxazoline compound represented by formula (I); wherein the isoxazoline compound of formula (I) is flurellanil; b) a second container having an aqueous carrier comprising one or more suspending agents, wetting agents and / or preservatives and water; and c) instructions for reconstituting the moxidectin microspheres and isoxazoline compound particles with an aqueous carrier prior to subcutaneous or intramuscular injection into an animal; The moxidectin microspheres and / or isoxazoline compound particles have a volume-weighted particle size distribution D50 of 75 μm to 150 μm as measured by a static light scattering instrument.
2. The kit according to claim 1, wherein the fat, wax or mixture thereof in the moxidectin microspheres has a melting point above 40°C.
3. The kit according to claim 1 or 2, wherein the moxidectin microspheres comprise 75% to 95% by weight of fat, wax or a mixture thereof.
4. The kit according to any one of claims 1 to 3, wherein the fat, wax or mixture thereof comprises fatty acid esters.
5. The kit according to claim 4, wherein the fatty acid esters are triglycerides of fatty acids, each of which contains 12 to 22 carbon atoms.
6. The kit according to claim 5, wherein the fatty acid ester is tristearin.
7. The kit according to any one of claims 1 to 6, wherein the moxidectin microspheres comprise moxidectin in an amount of 9-12% by weight and tristearin in an amount of 87-92% by weight.
8. The kit according to any one of claims 1 to 7, wherein the isoxazoline compound particles have a thickness greater than 10 μm but less than 100 μm as measured by scanning electron microscopy. 9 . The kit according to claim 8 , wherein the isoxazoline compound particles have a thickness greater than 30 μm but less than 80 μm.
10. The kit according to any one of claims 1 to 9, wherein the volume-weighted particle size D10 of the moxidectin microspheres and / or isoxazoline compound particles measured by static light scattering is 20 to 35 μm, the particle size D50 is 90 to 105 μm, and the particle size D90 is 155 to 175 μm.
11. A kit according to any one of claims 1 to 10, wherein the suspending agent in an aqueous carrier is selected from sodium carboxymethylcellulose, polyvinylpyrrolidone and methylcellulose.
12. The kit according to claim 8, wherein the isoxazoline compound particles have a thickness greater than 20 μm but less than 90 μm as measured by scanning electron microscopy.
13. An injectable veterinary suspension composition comprising the moxidectin microspheres according to any one of claims 1 to 10, the isoxazoline compound particles of formula (I) according to claims 1, or 6 to 10, and the aqueous carrier according to claim 1.
14. The composition of claim 13, wherein the aqueous carrier comprises from 0.5% to 15% by weight of a suspending agent, based on the weight of the composition.
15. The composition of claim 13, wherein the aqueous carrier comprises from 0.01% to 1.0%, by weight of the composition, of a wetting agent.
16. The composition of claim 15, wherein the wetting agent in the aqueous carrier is a poloxamer.
17. A method for preparing an injectable veterinary composition according to any one of claims 13 to 16, comprising the following steps: a) preparing the isoxazoline granules according to claim 1, or 6 to 10; b) preparing the moxidectin microspheres according to any one of claims 1 to 10 by melting fat, wax or a mixture thereof, adding moxidectin and an antioxidant, and preparing the microspheres by spinning disk atomization and sieving; c) filling the moxidectin microspheres obtained in step b) and the isoxazoline particles obtained in step a) into a first container; d) preparing an aqueous carrier as claimed in claim 1, or 13 to 16 by dissolving excipients including a suspending agent, a wetting agent and / or a preservative in water and introducing the aqueous carrier into a second container; e) reconstituting the moxidectin microspheres and isoxazoline particles by transferring the aqueous carrier from the second container d) to the first container; f) and shaking the first container to form a ready-to-use injectable veterinary suspension.
